Merck Adds Flagship To Its Venture Fund Network
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.
You may also be interested in...
Merck’s Iain Dukes On New BD Culture: Regional Hubs And Sourcing Innovation
Since Dukes arrived six months ago as head of Merck Research Labs’ licensing and external affairs, Merck has consolidated and restructured its scattered business development functions, rolled out its regional BD hubs, and rationalized the distinction between equity investments and venture fund investments
Amgen, Novartis Are Investors In Atlas Venture’s Ninth Fund
Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.
Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies
Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.